In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
The approval was driven by data from the Phase III TULIP-SC trial
India leads the shift as wellness tourism integrates healthcare, hospitality, and lifestyle
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
nSEPIA aims to bring structure to an area long dominated by subjectivity
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
Former Cipla MD & CEO to lead next phase of growth at science-led CDMO platform; Vivek Sharma transitions to advisory role
New minimally invasive biomarker test enables earlier diagnosis and improved clinical decision-making, aligned with global guidelines
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
Subscribe To Our Newsletter & Stay Updated
